Here you will find the Funding Position of CCG Commissioned High-Cost Drugs within the Lancashire and South Cumbria Health Economy
A number of High-Cost Drugs, devices, procedures and products have been excluded from the scope of the national tariff of Payment by Results. These are listed on tab 13b of the following document:
2024/25 Annex A: The national tariff workbook
High-cost drugs are commissioned by:
The funding position of medicines directly commissioned by NHS England can be accessed via the NHS England website
Refer to the Manual for Prescribed Specialised Services for further information about prescribed specialised services, some of which are directly commissioned by NHS England and some by CCGs.
Date Posted: 01 - Jun - 2018
Approval Mechanism: Prior Approval BLUETEQ form Available
Date Posted: 09 - Jul - 2021
Approval Mechanism: Blueteq form
Date Posted: 14 - Sep - 2022
Approval Mechanism: Blueteq form
Date Posted: 01 - May - 2013
Approval Mechanism:
Date Posted: 01 - Feb - 2016
Approval Mechanism: Prior Approval Blueteq Form Available
Rheumatoid arthritis (LSCMMG pathway)
Date Posted: 01 - May - 2013
Approval Mechanism: Prior Approval BLUETEQ form Available
Psoriatic arthritis (NICE TA199)
Date Posted: 01 - Nov - 2014
Approval Mechanism: Prior Approval BLUETEQ form Available
Second line in psoriatic arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy .
Date Posted: 01 - May - 2016
Approval Mechanism: Prior Approval BLUETEQ form Available
Use in high risk patients for prevention of recurrence or upon recurrence of Crohn's Disease following surgery.
Date Posted: 01 - Jun - 2015
Approval Mechanism: Prior Approval BLUETEQ form Available
Juvenile Idiopathic Arthritis (JIA) in Adult Patients
Date Posted: 01 - May - 2016
Approval Mechanism: N/A
Prevention of recurrence of ulcerative colitis following surgery
Date Posted: 01 - Jul - 2016
Approval Mechanism: Prior Approval BLUETEQ form Available
Second line biologic for moderate to severe active ulcerative colitis ONLY where patients have had adalimumab 1st line
Date Posted: 01 - May - 2013
Approval Mechanism: Prior Approval BLUETEQ form Available
Very severe plaque psoriasis (NICE TA134)
Date Posted: 01 - May - 2013
Approval Mechanism: Prior Approval BLUETEQ form Available
Acute exacerbations of Ulcerative Colitis (NICE TA163)
Date Posted: 01 - May - 2016
Approval Mechanism: Prior Approval BLUETEQ form Available
Crohn's disease, 2nd line biologic (NICE TA187) and LSCMMG Recommendation
Date Posted: 01 - May - 2016
Approval Mechanism: Prior Approval Blueteq Form Available
Crohn's disease, 1st line biologic (NICE TA187) and LSCMMG Recommendation
Date Posted: 01 - May - 2016
Approval Mechanism: Prior Approval BLUETEQ form Available
First line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LSCMMG Recommendation
Date Posted: 01 - Mar - 2016
Approval Mechanism: Prior Approval BLUETEQ form Available
Ankylosing spondylitis (NICE TA383)
Date Posted: 01 - May - 2017
Approval Mechanism: Prior Approval BLUETEQ form Available
Date Posted: 01 - Sep - 2018
Approval Mechanism: Prior Approval BLUETEQ form Available
Date Posted: 01 - Oct - 2019
Approval Mechanism: Prior approval blueteq form available
Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)
